EVLO News and Press, Evelo Biosciences Inc. From 03/02/22

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that Simba Gill, Ph.D., Chief Exe...

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs PR Newswire CAMBRIDGE, Mass. , Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology a...

Evelo Biosciences (NASDAQ:EVLO) said data from a post-treatment follow-up (Part B) of its phase 2 trial of EDP1815 in patients with mild and moderate psoriasis showed durable and deeper clinical responses. The EDP1815-201 phase 2 trial consisted of Part A, when patients received either E...

-18/30 patients maintained a PASI-50 or greater response at 24 weeks post-treatment- -9/20 patients experienced a deepening of response from PASI-50 to at least PASI-75 during post-treatment period- -No flare or rebound observed following discontinuation of treatment- -Evelo to host K...

Evelo Biosciences (NASDAQ:EVLO) said the first patient was dosed in a phase 2 trial of EDP1815 to treat patients with mild, moderate, and severe atopic dermatitis, also known as eczema. Results from the phase 2 study, dubbed EDP1815-207, are expected in 1H 2023. "Our previously...

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the first patient has been do...

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT PR Newswire CAMBRIDGE, Mass. , Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdepende...

Reporting data from a biomarker analysis of its Phase 2 trial for EDP1815 in patients with psoriasis, Evelo Biosciences (NASDAQ:EVLO) said that there was a statistically significant reduction in the release of pro-inflammatory cytokines following the oral treatment. The blood samples of 96 pa...

Treatment with EDP1815 led to reduced production of cytokines IL-6, IL-8, and TNF in blood cells Cytokine analysis supports gut-restricted action of EDP1815 to resolve inflammation throughout the body Reductions in IL-12b, IL-17, and IL-23 in skin lesions - all targets of ...

Palm Beach, FL –– February 3, 2022  – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination, inflammation, and degenerative changes such ...